SIRT1 is involved in various neurodegenerative diseases, including PD, Huntington's disease, amyotrophic lateral sclerosis, as well as AD.[8, 12, 14] Thus, SIRT1 may become a novel pharmacological target for neurodegenerative disease, in modulating specific cellular processes leading to the decrease of Aß expression in the brain.[8, 12, 14] We suggest that our hyperglycemic NV chip is suitable for the neurodegenerative pharmaceutic research by reflecting in vivo characteristics in response to the diabetic microenvironment. This evidence concerns the gene SIRT1 and juvenile Huntington disease.